Previous 10 | Next 10 |
The U.S. FDA has granted Fast Track designation to Aquestive Therapeutics' (NASDAQ:AQST) AQST-109, its epinephrine-based candidate for the treatment of severe allergic reactions. Shares are up 14% in premarket trading. AQST-109 is different from other epinephrine products in that it...
WARREN, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced that the U.S....
Image source: The Motley Fool. Aquestive Therapeutics, Inc. (NASDAQ: AQST) Q4 2021 Earnings Call Mar 09, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Aquestive Therapeutics, Inc. (AQST) Q4 2021 Earnings Call Tran...
Aquestive Therapeutics, Inc. (AQST) Q4 2021 Earnings Conference Call March 9, 2022 08:00 ET Company Participants Bennett Watson - Investor Relations Keith Kendall - Chief Executive Officer Ernie Toth - Chief Financial Officer Dan Barber - Chief Operating Officer Conference Call Participants G...
Aquestive Therapeutics press release (NASDAQ:AQST): FY GAAP EPS of -$1.85 misses by $0.36. Revenue of $50.83M (+10.9% Y/Y) beats by $1.73M. For further details see: Aquestive Therapeutics GAAP EPS of -$1.85 misses by $0.36, revenue of $50.83M beats by $1.73M
Continues to interact with FDA regarding orphan drug review of the NDA for Libervant™ (diazepam) Buccal Film Reports start of Part 2 of EPIPHAST crossover study for AQST-109 epinephrine oral film after positive Part 1 data Enters license, development and supply agreement fo...
Suzhou antibody company Adagene will apply its masking technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights (ex-Japan) for two Heidelberg Pharma ADC candidates with options on two more in a deal potentia...
Gainers: DBV Technologies (NASDAQ:DBVT) +16%. EyePoint Pharmaceuticals (NASDAQ:EYPT) +14%. Antares Pharma (NASDAQ:ATRS) +10%. Nuvalent (NASDAQ:NUVL) +8%. Aquestive Therapeutics (NASDAQ:AQST) +7%. Losers: NuCana (NASDAQ:NCNA) -54%. MediWound (NASDAQ:MDWD) -15%....
WARREN, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives...
WARREN, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, presented a late breaking p...
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs) Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pr...
WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...